A New Era in Treating Low Libido in Men

A new step by the US Food and Drug Administration (FDA) to expand the uses of testosterone replacement therapy (TRT) has reignited a notable debate in men’s health. In past years, testosterone therapy was used in very limited settings because of possible risks to heart and blood vessel health.

Until now, testosterone therapy has been officially approved only for men with testosterone deficiency due to genetic or structural causes. However, experts have long argued that current regulations lag behind clinical practice.

Some urologists and endocrinologists note that many patients experiencing low libido, loss of energy and reduced quality of life can benefit from treatment even if they do not technically meet the current criteria. The FDA’s removal last year of the warning on heart attack and stroke risk for testosterone products was also interpreted as a sign that the regulatory approach has begun to soften.

Nevertheless, testosterone therapy remains a controversial area. In particular, online clinics aggressively recommending hormone therapy to men with normal testosterone levels are raising concerns about overdiagnosis and unnecessary treatment.

In conclusion, the FDA’s new approach may make testosterone therapy more accessible. However, experts emphasize that clinical benefit must be carefully distinguished from unnecessary hormone use.

Source: Bankhead C. "FDA Takes Steps to Expand Testosterone for Men's Libido." MedPage Today. Published: April 17, 2026.